In clinical trials
Digestive & weight
PN-943
Evidence
Clinical trials
Class
Oral gut-restricted integrin antagonist peptide
KEY TAKEAWAY
PN-943 is an oral peptide designed to block the alpha-4 beta-7 integrin, a molecule that lets inflammatory immune cells enter the lining of the gut. PN-943 is not FDA-approved and has been tested in phase 2 trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Oral gut-restricted integrin antagonist peptide
Being studied for
Studied in ulcerative colitis
Key fact
PN-943 is not FDA-approved and has been tested in phase 2 trials.
Route
Oral capsule in trials
Evidence strength
Clinical trials
PN-943 is an oral peptide designed to block the alpha-4 beta-7 integrin, a molecule that lets inflammatory immune cells enter the lining of the gut.
By blocking that integrin, it aims to reduce immune cell entry into the intestine while staying mostly in the gut rather than the bloodstream.
PN-943 is not FDA-approved and has been tested in phase 2 trials.
Studied in ulcerative colitis.
Early trials reported it was generally well tolerated, but data are limited.
PN-943: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.